Abstract: Objective: To assess the therapeutic effects of topical benvitimod in AD-like murine models induced by calcipotriol (MC903). Methods: Of 36 AD BALB/c murine models, 6 were as normal controls and 30 were induced by MC903, and then, were divided into 5 groups: matrix group, 0.5% benzymoid group, 1.0% benzymoid group, 0.1% mometasone furoate group and 0.1% tacrolimus group (6 mice in each group). The levels of lesion’s thickness and TEWL,CD4+T cells and TSLP protein in the lesions were assessed before and after treatment. Results: After treatment, the levels of dermatitis score, lesion’s thickness, TEWL, CD4+T cells and TSLP in 0.5% and 1.0% benvitimod group were lower than those in the matrix group (Ps<0.05). 1.0% benvitimod was more effective than 0.5% benzymoid and tarcrolimus. The efficacy of 1.0% benvitimod was equivalent?to 0.1% mometasone furoate (P>0.05). Conclusion: Topical benvitimod can improve AD-like symptoms in BALB/c murine models.

Key words: atopic dermatitis, benvitimod, murine model